<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml">
   <div xmlns="" tagx="article">
      <head>
         <style type="text/css"> table, tr, td {border : thin;}</style>
         <span class="citation_publisher">BioMed Central</span>
         <h2 class="citation-title">Behavioral and antioxidant activity of a tosylbenz[g]indolamine derivative. A proposed
            better profile for a potential antipsychotic agent
         </h2>
         <span class="doi">10.1186/1475-2832-3-1</span>
         <div class="contrib-group">contrib: 
            	  CONT
            	  
            <span class="citation_author">Chara A Zika</span>
            <span class="citation_author_institution_ref"></span>
            <span class="citation_author">Ioannis Nicolaou</span>
            <span class="citation_author_institution_ref"></span>
            <span class="citation_author">Antonis Gavalas</span>
            <span class="citation_author_institution_ref"></span>
            <span class="citation_author">George V Rekatas</span>
            <span class="citation_author_institution_ref"></span>
            <span class="citation_author">Ekaterini Tani</span>
            <span class="citation_author_institution_ref"></span>
            <span class="citation_author">Vassilis J Demopoulos</span>
            <span class="citation_author_institution_ref"></span>
         </div>
         <span class="email">[]</span>
         <span class="conflict">[]</span>
         <span class="contribs">[]</span>
         <span class="citation_pubdate">[2004-1-7]</span>
         <span class="citation_copyright">[Copyright 2004: Zika et al; licensee BioMed Central Ltd. This is an Open Access article:
            verbatim copying and redistribution of this article are permitted in all media for
            any purpose, provided this notice is preserved along with the article's original URL.]
         </span>
         <span class="citation_licence">[Licence ]</span>
         <span class="citation_funding">[]</span>
         <span class="citation_pagecount">[]</span>
         <span class="citation_data">[]</span>
      </head>
      <div id="abstract" tag="abstract">
         <h2>Abstract</h2>
         <div id="">
            <h2>Background</h2>
            <p xmlns:xlink="http://www.w3.org/1999/xlink">Tardive dyskinesia (TD) is a major limitation of older antipsychotics. Newer antipsychotics
               have various other side effects such as weight gain, hyperglycemia, etc. In a previous
               study we have shown that an indolamine molecule expresses a moderate binding affinity
               at the dopamine D
               <div tagxxx="sub">2 </div>and serotonin 5-HT
               <div tagxxx="sub">1A </div>receptors in in vitro competition binding assays. In the present work, we tested its
               p-toluenesulfonyl derivative (TPBIA) for behavioral effects in rats, related to interactions
               with central dopamine receptors and its antioxidant activity.
            </p>
         </div>
         <div id="">
            <h2>Methods</h2>
            <p xmlns:xlink="http://www.w3.org/1999/xlink">Adult male Fischer-344 rats grouped as: i) Untreated rats: TPBIA was administered
               i.p. in various doses ii) Apomorphine-treated rats: were treated with apomorphine
               (1 mg kg
               <sup>-1</sup>, i.p.) 10 min after the administration of TPBIA. Afterwards the rats were placed
               individually in the activity cage and their motor behaviour was recorded for the next
               30 min The antioxidant potential of TPBIA was investigated in the model of in vitro
               non enzymatic lipid peroxidation.
            </p>
         </div>
         <div id="">
            <h2>Results</h2>
            <p xmlns:xlink="http://www.w3.org/1999/xlink">i) In non-pretreated rats, TPBIA reduces the activity by 39 and 82% respectively,
               ii) In apomorphine pretreated rats, TPBIA reverses the hyperactivity and stereotype
               behaviour induced by apomorphine. Also TPBIA completely inhibits the peroxidation
               of rat liver microsome preparations at concentrations of 0.5, 0.25 and 0.1 mM.
            </p>
         </div>
         <div id="">
            <h2>Conclusion</h2>
            <p xmlns:xlink="http://www.w3.org/1999/xlink">TPBIA exerts dopamine antagonistic activity in the central nervous system. In addition,
               its antioxidant effect is a desirable property, since TD has been partially attributed,
               to oxidative stress. Further research is needed to test whether TPBIA may be used
               as an antipsychotic agent.
            </p>
         </div>
      </div>
      <div id="">
         <h2>Background</h2>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">It is well established that compounds which interact with central dopamine receptors
            have therapeutic potential in the treatment of conditions like Parkinson's disease
            and psychotic disorders. For the later treatment, it is known that tardive dyskinesia
            (TD) is a major limitation of chronic antipsychotic drug therapy at least with older
            (typical) antipsychotics.
         </p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">There is increased awareness of the different ways in which this condition manifests
            itself and the variety of disabilities that TD produces. Although a substantial research
            has been stimulated to identify the underlying pathophysiological mechanisms of TD,
            they remain largely elusive. There are several hypotheses about the pathophysiology
            of TD (dopamine hypersensitivity, neurotoxicity, GABA insufficiency, noradrenergic
            dysfunction, structural abnormalities)[
            <span ref-type="bibr" rid="B1">
               <sup>
                  <a href="#B1">1</a>
               </sup>
            </span>], however the true mechanism remains unknown.
         </p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">The hypothesis of dopamine hypersensitivity proposes that the nigrostriatal dopamine
            system develops increased sensitivity to dopamine as a consequence of chronic dopamine
            receptor blockade induced by neuroleptic drugs. There is an increased incidence and
            prevalence of involuntary hyperkinetic dyskinesia in patients receiving dopamine antagonists
            in most [
            <span ref-type="bibr" rid="B1">
               <sup>
                  <a href="#B1">1</a>
               </sup>
            </span>-
            <span ref-type="bibr" rid="B3">
               <sup>
                  <a href="#B3">3</a>
               </sup>
            </span>] but not all reports [
            <span ref-type="bibr" rid="B4">
               <sup>
                  <a href="#B4">4</a>
               </sup>
            </span>,
            <span ref-type="bibr" rid="B5">
               <sup>
                  <a href="#B5">5</a>
               </sup>
            </span>]. Dopamine antagonists usually suppress TD, whereas dopamine agonists aggravate TD
            symptoms [
            <span ref-type="bibr" rid="B6">
               <sup>
                  <a href="#B6">6</a>
               </sup>
            </span>].
         </p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">An alternate, though highly speculative hypothesis, is the proposal that TD is due
            to neurotoxic effects induced by free radical byproducts from catecholamine metabolism.
            The basal ganglia, by virtue of their high oxidative metabolism, are vulnerable to
            membrane lipid peroxidation as a result of the increased catecholamine turnover induced
            by neuroleptic drugs [
            <span ref-type="bibr" rid="B7">
               <sup>
                  <a href="#B7">7</a>
               </sup>
            </span>-
            <span ref-type="bibr" rid="B9">
               <sup>
                  <a href="#B9">9</a>
               </sup>
            </span>]. It is known that vitamin E (a-tocopherol) serves as a free radical scavenger, thus
            reducing the cytotoxic effects of free radicals. Clinical studies have produced conflicting
            data in this area. The impression gained from these studies was that while vitamin
            E is safe and well-tolerated, it confers only modest benefits. Some studies do not
            support the hypothesis that TD is mediated through free radical damage to neurons
            [
            <span ref-type="bibr" rid="B8">
               <sup>
                  <a href="#B8">8</a>
               </sup>
            </span>,
            <span ref-type="bibr" rid="B10">
               <sup>
                  <a href="#B10">10</a>
               </sup>
            </span>,
            <span ref-type="bibr" rid="B11">
               <sup>
                  <a href="#B11">11</a>
               </sup>
            </span>] while others support that vitamin E appears to be effective in reducing the severity
            of TD, especially in patients who are young and have recently developed TD [
            <span ref-type="bibr" rid="B12">
               <sup>
                  <a href="#B12">12</a>
               </sup>
            </span>,
            <span ref-type="bibr" rid="B13">
               <sup>
                  <a href="#B13">13</a>
               </sup>
            </span>].
         </p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">Early neuroleptic agents showed great antipsychotic promise initially, however, the
            induction of extrapyramidal side effects associated with their use constituted a significant
            problem. Atypical antipsychotics possess a lower extrapyramidal side effects liability
            and show a better efficacy in the treatment of negative and depressive symptoms as
            well as cognitive disorders associated with schizophrenia. These features have been
            related to a higher affinity to serotonin receptors. However, they brought about various
            side effects such as weight gain, hyperglycemia, cholesterol level elevation, and
            QT interval prolongation [
            <span ref-type="bibr" rid="B14">
               <sup>
                  <a href="#B14">14</a>
               </sup>
            </span>].
         </p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">A novel antipsychotic agent with a mechanism of action different from all currently
            marketed typical and atypical antipsychotics is aripiprazole. This quinoline derivative
            exerts potent partial agonistic action on D
            <div tagxxx="sub">2 </div>and 5-HT
            <div tagxxx="sub">1A </div>receptors and antagonistic properties at 5-HT
            <div tagxxx="sub">2A </div>receptors. Aripiprazole claims to be the first agent of a third generation of antipsychotics,
            the so-called "dopamine-serotonin stabilizers"[
            <span ref-type="bibr" rid="B14">
               <sup>
                  <a href="#B14">14</a>
               </sup>
            </span>].
         </p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">In a previous study [
            <span ref-type="bibr" rid="B15">
               <sup>
                  <a href="#B15">15</a>
               </sup>
            </span>] we have shown that 6,7,8,9-tetrahydro-N,N,-di-n-propyl-1
            <i>H</i>-benz [g]indole-7-amine (
            <b>PBIA</b>) (Figure 
            <span ref-type="fig" rid="F1">1</span>) acts 
            <i>in vivo </i>as a functional dopamine receptor partial agonist. It is known that a partial agonist
            at any dose level can not produce the same maximal biological response as a full agonist
            even though the partial agonist binds as tightly and as well to the receptor as the
            full agonist. In sum, a partial agonist has high affinity for its receptor, but low
            intrinsic activity. 
            <b>PBIA </b>is a moderate [
            <sup>3</sup>H]-spiperone and 8-OH-[
            <sup>3</sup>H]-DPAT competitor. Spiperone is a selective D
            <div tagxxx="sub">2 </div>antagonist while 8-OH-DPAT is a selective 5-HT
            <div tagxxx="sub">1A </div>agonist. This means that 
            <b>PBIA </b>expresses a moderate binding affinity at the dopamine D
            <div tagxxx="sub">2 </div>and serotonin 5-HT
            <div tagxxx="sub">1A </div>receptors in 
            <i>in vitro </i>competition binding assays.
         </p>
         <div tagxxx="fig">
            <span class="label">Figure 1</span>
            <caption xmlns:xlink="http://www.w3.org/1999/xlink">
               <p>Structure of 6,7,8,9-tetrahydro-N,N,-di-n-propyl-1
                  <i>H</i>-benz [g]indole-7-amine (PBIA), 1-p-toluenesulfonyl-6,7,8,9-tetrhydro-N,N-di-n-propyl-1
                  <i>H</i>-benz [g]indol-7-amine (TPBIA) and 5-OH-DPAT
               </p>
            </caption>
            <div tagxxx="graphic"></div>
         </div>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">
            <b>PBIA </b>was designed as a metabolically stable bioisostere of the potent dopamine receptor
            agonist 5-OH-DPAT, (Figure 
            <span ref-type="fig" rid="F1">1</span>). Phenolic dopamine receptor agonists suffer from poor bioavailability due to rapid
            metabolic inactivation via conjugation. Thus, an approach which has been pursued to
            overcome this problem is to develop non phenolic heterocyclic analogues. In this respect,
            evidence indicates that an indole NH moiety can be a bioisostere of the hydrogen-bonding
            H donor properties of the phenolic OH group in dopamine agonists. Based on the above,
            we synthesized 
            <b>PBIA</b>.
         </p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">In the present work, we tested the derivative 
            <b>2 </b>(Figure 
            <span ref-type="fig" rid="F1">1</span>), 1-p-toluenesulfonyl-6,7,8,9-tetrhydro-N,N-di-n-propyl-1
            <i>H</i>-benz [g]indol-7-amine (
            <b>TPBIA</b>) for behavioral effects in rats, related to interactions with central dopamine receptors.
            Because 
            <b>TPBIA </b>has an increased lipophilicity and an appropriate polar molecular surface area (PSA)
            value, we hypothesized that it might be capable of penetrating the blood-brain barrier
            in a considerable degree. Additionally, the presence of the tosyl group might shift
            the agonistic activity to that of an antagonist. It is documented that increasing
            the van der Waals molecular volume of an agonist makes it an antagonist [
            <span ref-type="bibr" rid="B16">
               <sup>
                  <a href="#B16">16</a>
               </sup>
            </span>]. Finally, since free radical and oxidative stress may be implicated in the pathophysiology
            of a number of neurodegenerative diseases [
            <span ref-type="bibr" rid="B17">
               <sup>
                  <a href="#B17">17</a>
               </sup>
            </span>] we also investigated the antioxidant potential of 
            <b>TPBIA</b>, since there are some reports concerning the role of free radicals in TD [
            <span ref-type="bibr" rid="B7">
               <sup>
                  <a href="#B7">7</a>
               </sup>
            </span>].
         </p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">Therefore, it becomes interesting to design compounds that maintain antipsychotic
            efficacy and simultaneously could be free of TD risk.
         </p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">The aim of the current study was:</p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">1) to find if 
            <b>TPBIA </b>crosses the blood-brain barrier,
         </p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">2) to test the behavioral effects of 
            <b>TPBIA </b>with specific focus on neuroleptic effects,
         </p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">3) to test its antioxidant activity.</p>
      </div>
      <div id="">
         <h2>Materials and Methods</h2>
         <div id="">
            <h3>Synthesis of TPBIA</h3>
            <p xmlns:xlink="http://www.w3.org/1999/xlink">Key step of the synthesis was a Mukaiyama type aldol condensation between the dimethyl
               acetal of 1-(
               <i>p</i>-toluenesulfonyl)pyrrole-3-acetaldehyde and 4-di-
               <i>n</i>-propylamino-1-trimethylsilyloxycyclohexene followed by cycloaromatization under acidic
               conditions. A detailed description of the procedures can be found elsewhere [
               <span ref-type="bibr" rid="B18">
                  <sup>
                     <a href="#B18">18</a>
                  </sup>
               </span>]. TPBIA was isolated as its hydrochloride salt. It was a white crystalline solid
               with melting point of 209–211°C. The salt was soluble in water in contrast to its
               free base form.
            </p>
         </div>
         <div id="">
            <h3>Experimental Animals</h3>
            <p xmlns:xlink="http://www.w3.org/1999/xlink">Adult male Fischer-344 rats (~250 g) were used.</p>
            <p xmlns:xlink="http://www.w3.org/1999/xlink">The experimental animals were grouped as:</p>
            <p xmlns:xlink="http://www.w3.org/1999/xlink">i. 
               <i>Group A: Untreated rats</i>: 
               <b>TPBIA </b>was administered i.p. in various doses and immediately afterwards the rats were placed
               individually in the activity cage and their motor behavior was recorded for the next
               30 min.
            </p>
            <p xmlns:xlink="http://www.w3.org/1999/xlink">ii. 
               <i>Group B: Apomorphine-treated rats</i>: the motor activity was measured as described above in the rats treated with apomorphine
               (1 mg kg
               <sup>-1</sup>, i.p.) 10 min after the administration of TPBIA.
            </p>
         </div>
         <div id="">
            <h3>Biological Experimental Procedure</h3>
            <div id="">
               <h3>in vivo</h3>
               <p xmlns:xlink="http://www.w3.org/1999/xlink">The experiments were conducted according to a previous reported methodology [
                  <span ref-type="bibr" rid="B15">
                     <sup>
                        <a href="#B15">15</a>
                     </sup>
                  </span>]. 
                  <b>TPBIA </b>was converted to its hydrochloride salt and dissolved in water. Apomorphine was dissolved
                  in 1 mM citric acid solution. The motor activity of the rats was measured between
                  12-6 pm in an Ugo-Basile activity cage (type 7401) (Figure 
                  <span ref-type="fig" rid="F2">2</span>).
               </p>
               <div tagxxx="fig">
                  <span class="label">Figure 2</span>
                  <caption xmlns:xlink="http://www.w3.org/1999/xlink">
                     <p>The Ugo-Basile activity cage (type 7401)</p>
                  </caption>
                  <div tagxxx="graphic"></div>
               </div>
            </div>
            <div id="">
               <h3>in vitro</h3>
               <p xmlns:xlink="http://www.w3.org/1999/xlink">The antioxidant potential of 
                  <b>TPBIA </b>was investigated in the model of 
                  <i>in vitro </i>non enzymatic lipid peroxidation [
                  <span ref-type="bibr" rid="B19">
                     <sup>
                        <a href="#B19">19</a>
                     </sup>
                  </span>].
               </p>
               <p xmlns:xlink="http://www.w3.org/1999/xlink">The experiments were conducted according to a previous reported methodology [
                  <span ref-type="bibr" rid="B15">
                     <sup>
                        <a href="#B15">15</a>
                     </sup>
                  </span>]. Hepatic microsomal fractions prepared from untreated male Fischer-344 rats were
                  heat-inactivated (90°C, 90 s) and suspended in Tris-HCl/KCl buffer (50 mM/150 mM,
                  pH 7.4). The incubation mixtures contained the microsomal fraction, corresponding
                  to 0.125 g liver mL
                  <sup>-1</sup>, ascorbic acid (0.2 mM) in Tris buffer, and various concentrations (0.01–1 mM) of
                  the tested compounds dissolved in DMSO. An equal volume of the solvent (0.1 mL) was
                  added to the control incubate. The reaction was initiated by adding freshly prepared
                  FeSO
                  <div tagxxx="sub">4 </div>solution (10 μM). The mixture was incubated at 37°C for 45 min. Aliquots (0.3 mL)
                  of the incubation mixture (final volume 4 mL) were taken at various time intervals.
                  Lipid peroxidation was assayed spectrophotometrically (535 nm against 600 nm) by determination
                  of the 2-thiobarbituric acid reactive material.
               </p>
               <p xmlns:xlink="http://www.w3.org/1999/xlink">Antioxidants inhibit the production of malondialdehyde and, therefore, the color produced
                  after addition of 2-thiobarbituric acid is less intense. None of the compounds interfered
                  with the assay, neither with the conjugation of 2-thiobarbituric acid or with the
                  absorption at 535–600 nm. Each experiment was performed at least in duplicate. The
                  UV measurements were carried out on a Perkin-Elmer 554 spectrophotometer.
               </p>
            </div>
         </div>
      </div>
      <div id="">
         <h2>Results</h2>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">The effect of the 
            <b>TPBIA </b>on the motor behavior of non treated and apomorphine pretreated rats are shown in
            Tables 
            <span ref-type="table" rid="T1">
               <a href="#T1">1</a>
            </span>, 
            <span ref-type="table" rid="T2">
               <a href="#T2">2</a>
            </span> and Figure 
            <span ref-type="fig" rid="F3">3</span>. Apomorphine is a selective agonist of the dopamine D2 receptors. It was found that:
         </p>
         <div id="T1">
            <span class="label">Table 1</span>
            <caption xmlns:xlink="http://www.w3.org/1999/xlink">
               <p>Motor behavior of untreated rats</p>
            </caption>
            <table xmlns:xlink="http://www.w3.org/1999/xlink">
               <thead>
                  <tr>
                     <td>Compound (dose, μmol Kg
                        <sup>-1</sup>)
                     </td>
                     <td>Movements (±SEM) / 30 min</td>
                     <td>Compared with the control group (%)</td>
                  </tr>
               </thead>
               <div tagxxx="tbody">
                  <tr>
                     <td>Controls</td>
                     <td>263(81)</td>
                     <td>100</td>
                  </tr>
                  <tr>
                     <td>TPBIA(40)</td>
                     <td>161(22)
                        <sup>NS</sup>
                     </td>
                     <td>61</td>
                  </tr>
                  <tr>
                     <td>TPBIA(80)</td>
                     <td>46(16)**</td>
                     <td>18</td>
                  </tr>
               </div>
            </table>
            <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink">
               <p>
                  <sup>NS</sup>, P &gt; 0.05 (not significant) and **P &lt; 0.01 according to Student's test, n = 3–6
               </p>
            </table-wrap-foot>
         </div>
         <div id="T2">
            <span class="label">Table 2</span>
            <caption xmlns:xlink="http://www.w3.org/1999/xlink">
               <p>Motor behavior of apomorphine treated rats</p>
            </caption>
            <table xmlns:xlink="http://www.w3.org/1999/xlink">
               <thead>
                  <tr>
                     <td>Compound (dose, μmol Kg
                        <sup>-1</sup>)
                     </td>
                     <td>Movements (± SEM) / 30 min</td>
                     <td>Compared with the control group (%)</td>
                  </tr>
               </thead>
               <div tagxxx="tbody">
                  <tr>
                     <td>Apomorphine treated controls</td>
                     <td>385(68)</td>
                     <td>100</td>
                  </tr>
                  <tr>
                     <td>TPBIA(80)</td>
                     <td>113(28)**</td>
                     <td>29</td>
                  </tr>
               </div>
            </table>
            <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink">
               <p>**P &lt; 0.01 according to Student's test, n = 4</p>
            </table-wrap-foot>
         </div>
         <div tagxxx="fig">
            <span class="label">Figure 3</span>
            <caption xmlns:xlink="http://www.w3.org/1999/xlink">
               <p>Effect of 
                  <b>TPBIA </b>on the motor behavior of experimental animals
               </p>
            </caption>
            <div tagxxx="graphic"></div>
         </div>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">i. In non-pretreated rats, 
            <b>TPBIA </b>at doses of 40 and 80 μmol/kg reduces the activity by 39 and 82% respectively (Number
            of experimental animals: 3–6).
         </p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">ii. In apomorphine pretreated rats, 
            <b>TPBIA </b>(80 μmol/kg) reverses the hyperactivity and stereotype behavior induced by apomorphine
            (Number of experimental animals: 4).
         </p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">The time course of non enzymatic lipid peroxidation as affected by 0.5, 0.25 and 0.1
            mM concentrations of 
            <b>TPBIA </b>is shown in Figure 
            <span ref-type="fig" rid="F4">4</span>.
         </p>
         <div tagxxx="fig">
            <span class="label">Figure 4</span>
            <caption xmlns:xlink="http://www.w3.org/1999/xlink">
               <p>Time course of lipid peroxidation as affected by various concentrations of 
                  <b>TPBIA</b>.
               </p>
            </caption>
            <div tagxxx="graphic"></div>
         </div>
      </div>
      <div id="">
         <h2>Discussion</h2>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">The results support our hypothesis that:</p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">
            <b>a) </b>TPBIA crosses the blood-brain barrier,
         </p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">
            <b>b) </b>modifies the motor behavior of the experimental animals,
         </p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">
            <b>c) </b>shows antioxidant activity.
         </p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">
            <b>a) </b>The Polar Surface Area (PSA) of a molecule is defined as the area of its van der Waals
            surface that arises from oxygen and nitrogen atoms as well as hydrogen atoms attached
            to oxygen or nitrogen atoms. As such, it is clearly related to the capacity of a compound
            to form hydrogen bonds. PSA has been established as a valuable physicochemical parameter
            for the prediction of a number of properties related to the pharmacokinetic profile
            of drugs. Among these properties are the intestinal absorption and the blood-brain
            barrier penetration. PSA has been found to be useful in modeling intestinal absorption
            together with a direct estimate of lipophilicity widely acknowledged as an important
            factor in transport across membranes. A common measure of the degree of BBB penetration
            is the ratio of the steady-state concentrations of the drug molecule in the brain
            and in the blood, usually expressed as log(Cbrain/Cblood). We expect that the increased
            lipophilicity (calculated [
            <span ref-type="bibr" rid="B20">
               <sup>
                  <a href="#B20">20</a>
               </sup>
            </span>] ClogP = 6.659) and the small PSA value (calculated [
            <span ref-type="bibr" rid="B21">
               <sup>
                  <a href="#B21">21</a>
               </sup>
            </span>], 38.9 Angstroems
            <sup>2</sup>) of this compound will facilitate its central nervous system penetration. Thus by
            using an equation reported by Clark et al [
            <span ref-type="bibr" rid="B22">
               <sup>
                  <a href="#B22">22</a>
               </sup>
            </span>] we found that the steady-state distribution of 
            <b>TPBIA </b>between brain and blood is approximately 1000/1 (logBB = 0.58). This computational
            model contains two variables: PSA and calculated logP, both of which can be rapidly
            computed. The model could be considered reliable; for example the measured and predicted
            BBB permeability of the antidepressant drug, amitryptyline were quite similar (experimental
            logBB = 0.76–0.98 and calculated logBB = 0.76). Finally, its low PSA value is a strong
            indication that it could be used 
            <i>per os </i>for systematic use [
            <span ref-type="bibr" rid="B23">
               <sup>
                  <a href="#B23">23</a>
               </sup>
            </span>].
         </p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">
            <b>b) </b>The presented results could suggest that 
            <b>TPBIA </b>acts as a dopamine receptor antagonist in the central nervous system. The tosyl group
            in 
            <b>TPBIA</b>, which plain was found to be perpendicular to that of the indole ring in its low
            energy conformation (Figure 
            <span ref-type="fig" rid="F4">4</span>) [
            <span ref-type="bibr" rid="B24">
               <sup>
                  <a href="#B24">24</a>
               </sup>
            </span>] is important to the differentiation of the biological profile between compounds
            
            <b>PBIA </b>and 
            <b>TPBIA</b>. The association of increasing molecular weight with increasing antagonistic power
            is well known. An antagonist is always bulkier than the corresponding agonist and
            it is obvious that the likelihood of forming extra van der Waals bonds with the receptor
            increases the chances of the bulkier molecule having a longer retention time. Because
            a molecule's kinetic energy of translation (which is an important factor in desorption)
            does not change with increase in molecular weight, any gain in size by the molecule
            increases its time of residence on the receptor [
            <span ref-type="bibr" rid="B16">
               <sup>
                  <a href="#B16">16</a>
               </sup>
            </span>].
         </p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">
            <b>c) </b>Some clinical studies [
            <span ref-type="bibr" rid="B6">
               <sup>
                  <a href="#B6">6</a>
               </sup>
            </span>,
            <span ref-type="bibr" rid="B25">
               <sup>
                  <a href="#B25">25</a>
               </sup>
            </span>] have shown that vitamin E (a well established antioxidant) may be effective in treating
            TD. However vitamin E does not cross readily the blood-brain barrier [
            <span ref-type="bibr" rid="B26">
               <sup>
                  <a href="#B26">26</a>
               </sup>
            </span>], which could explain why other studies failed to confirm these results [
            <span ref-type="bibr" rid="B6">
               <sup>
                  <a href="#B6">6</a>
               </sup>
            </span>]. Therefore we considered interesting to investigate the antioxidant potential of
            the synthesized 
            <b>TPBIA</b>. It was found that 
            <b>TPBIA </b>completely inhibits the peroxidation of rat liver microsome preparations at the studied
            concentrations
         </p>
      </div>
      <div id="">
         <h2>Conclusion</h2>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">The results of the current study suggest that 
            <b>TPBIA </b>crosses the blood-brain barrier, possesses neuroleptic activity and exerts antioxidative
            activity. The above constitute preliminary 
            <i>in vivo/vitro </i>evidence suggesting that 
            <b>TPBIA </b>could merit further investigation as a potential candidate as an antipsychotic agent
            with novel and clinically important properties.
         </p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">A putative combination of dopaminergic antagonism and antioxidant activity of a compound
            which readily cross the blood-brain barrier could be of pharmaceutical interest especially
            when the compound is used for the treatment of behavioral disorders in the frame of
            an organic or degenerative mental disorder.
         </p>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">The above results indicate that 
            <b>TPBIA </b>might have therapeutic potential in the treatment of psychosis, due to its dopamine
            antagonistic activity in the central nervous system. In addition, its antioxidant
            effects is a desirable property, since tardive dyskinesia – a neuroleptics' severe
            side effect – has been attributed, at least in part, to oxidative stress.
         </p>
      </div>
      <div id="">
         <h2>Conflict of interest</h2>
         <p xmlns:xlink="http://www.w3.org/1999/xlink">None declared.</p>
         <div tagxxx="fig">
            <span class="label">Figure 5</span>
            <caption xmlns:xlink="http://www.w3.org/1999/xlink">
               <p>Low energy conformation and van der Waals surface of compound 
                  <b>TPBIA</b>
               </p>
            </caption>
            <div tagxxx="graphic"></div>
         </div>
      </div>
      <div tagxxx="back">
         <div tagxxx="ack">
            <div id="">
               <h2>Acknowledgment</h2>
               <p xmlns:xlink="http://www.w3.org/1999/xlink">This work was supported by the grants PENED91ED883 (D.V.J., G.A., R.G.V., T.E.), PENED99ED427
                  (D.V.J., N.I.) and P.D.E., E.P.A.N.-M.4.3.6.1., C.2000 SE 01330005 (D.V.J., N.I.,
                  Z.C.) from the General Secretariat of Research and Technology of Greece as well as
                  from the Public Benefit Foundation Alexander S. Onassis (Z.C.).
               </p>
            </div>
         </div>
         <div tag="ref-list">
            <ul>
               <li tag="ref">
                  <a name="B1"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Bloom</span>
                           <span tagx="given-names">F</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Kupfer</span>
                           <span tagx="given-names">D</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Psychopharmacology</span>
                     <span tagx="source">The fourth generation of progress</span>
                     <span tagx="year">1994</span>
                     <span class="publisher-name'">[New York: Raven Press]</span>
                     <span tagx="fpage">1497</span>
                     <span tagx="lpage">1498</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B2"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Kane</span>
                           <span tagx="given-names">JM</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Woerner</span>
                           <span tagx="given-names">M</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Weinhold</span>
                           <span tagx="given-names">P</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Wegner</span>
                           <span tagx="given-names">J</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Kinon</span>
                           <span tagx="given-names">B</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Borenstein</span>
                           <span tagx="given-names">M</span>,
                        </span>
                     </span>
                     <span tagx="article-title">Incidence of Tardive Dyskinesia: Five Year Data from a Prospective Study</span>
                     <span tagx="source">Psychopharmacol Bull</span>
                     <span tagx="year">1984</span>
                     <span tagx="volume">20</span>
                     <span tagx="fpage">39</span>
                     <span tagx="lpage">40</span>
                     <span class="pub-id'">[6144134]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B3"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Saltz</span>
                           <span tagx="given-names">BL</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Woerner</span>
                           <span tagx="given-names">M</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Kane</span>
                           <span tagx="given-names">JM</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Prospective study of tardive dyskinesia incidence in the elderly</span>
                     <span tagx="source">JAMA</span>
                     <span tagx="year">1991</span>
                     <span tagx="volume">266</span>
                     <span tagx="fpage">2402</span>
                     <span tagx="lpage">2406</span>
                     <span class="pub-id'">[1681122]</span>
                     <span class="pub-id'">[10.1001/jama.266.17.2402]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B4"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Waddington</span>
                           <span tagx="given-names">JL</span>,
                        </span>
                     </span>
                     <span tagx="article-title">Schizophrenia, affective psychosis and other disorders treated with neuroleptic drugs:
                        the enigma of tardive dyskinesia, its neurobiological determinants and the conflict
                        of paradigms
                     </span>
                     <span tagx="source">Int Rev Neurobiol</span>
                     <span tagx="year">1989</span>
                     <span tagx="volume">31</span>
                     <span tagx="fpage">297</span>
                     <span tagx="lpage">353</span>
                     <span class="pub-id'">[2574716]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B5"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Waddington</span>
                           <span tagx="given-names">JL</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Youssef</span>
                           <span tagx="given-names">HA</span>,
                        </span>
                     </span>
                     <span tagx="article-title">The lifetime outcome and involuntary movements of schizophrenia never treated with
                        neuroleptic drugs
                     </span>
                     <span tagx="source">Br J Psychiatry</span>
                     <span tagx="year">1990</span>
                     <span tagx="volume">156</span>
                     <span tagx="fpage">106</span>
                     <span tagx="lpage">108</span>
                     <span class="pub-id'">[1967543]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B6"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Adler</span>
                           <span tagx="given-names">LA</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Edson</span>
                           <span tagx="given-names">R</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Lavori</span>
                           <span tagx="given-names">P</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Peselow</span>
                           <span tagx="given-names">E</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Duncan</span>
                           <span tagx="given-names">E</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Rosenthal</span>
                           <span tagx="given-names">M</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Rostrosen</span>
                           <span tagx="given-names">J</span>,
                        </span>
                     </span>
                     <span tagx="article-title">Long-term treatment effects of vitamin E for tardive dyskinesia</span>
                     <span tagx="source">Biol Psych</span>
                     <span tagx="year">1998</span>
                     <span tagx="volume">43</span>
                     <span tagx="fpage">868</span>
                     <span tagx="lpage">872</span>
                     <span class="pub-id'">[10.1016/S0006-3223(97)00027-9]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B7"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Cadet</span>
                           <span tagx="given-names">JL</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Lohr</span>
                           <span tagx="given-names">JB</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Jeste</span>
                           <span tagx="given-names">DV</span>,
                        </span>
                     </span>
                     <span tagx="article-title">Free Radicals and Tardive Dyskinesia</span>
                     <span tagx="source">Trends Neurosci</span>
                     <span tagx="year">1986</span>
                     <span tagx="volume">9</span>
                     <span tagx="fpage">107</span>
                     <span tagx="lpage">108</span>
                     <span class="pub-id'">[10.1016/0166-2236(86)90035-4]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B8"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Lohr</span>
                           <span tagx="given-names">JB</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Cadet</span>
                           <span tagx="given-names">JL</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Lohr</span>
                           <span tagx="given-names">MA</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Vitamin E in the treatment of Tardive Dyskinesia. The possible involvement of free
                        Radical Mechanisms
                     </span>
                     <span tagx="source">Schizophrenia Bull</span>
                     <span tagx="year">1988</span>
                     <span tagx="volume">14</span>
                     <span tagx="fpage">291</span>
                     <span tagx="lpage">296</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B9"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Lohr</span>
                           <span tagx="given-names">JB</span>,
                        </span>
                     </span>
                     <span tagx="article-title">Oxygen Radicals and Neuropsychiatric Ilness, Some speculations</span>
                     <span tagx="source">Arch Gen Psychiatry</span>
                     <span tagx="year">1991</span>
                     <span tagx="volume">48</span>
                     <span tagx="fpage">1097</span>
                     <span tagx="lpage">1106</span>
                     <span class="pub-id'">[1845228]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B10"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">McCreadie</span>
                           <span tagx="given-names">RG</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">MacDonald</span>
                           <span tagx="given-names">E</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Wiles</span>
                           <span tagx="given-names">D</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">The Nithsdale Schizophrenia Surveys. XIV: Plasma lipid peroxide and serum vitamin
                        E levels in patients with and without tardive dyskinesia, and in normal subjects
                     </span>
                     <span tagx="source">Br J Psychiatry</span>
                     <span tagx="year">1995</span>
                     <span tagx="volume">167</span>
                     <span tagx="fpage">610</span>
                     <span tagx="lpage">617</span>
                     <span class="pub-id'">[8564316]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B11"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Adler</span>
                           <span tagx="given-names">LA</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Peselow</span>
                           <span tagx="given-names">E</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Rotrosen</span>
                           <span tagx="given-names">J</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Vitamine E treatment of Tardive Dyskinesia</span>
                     <span tagx="source">Am J Psychiat</span>
                     <span tagx="year">1993</span>
                     <span tagx="volume">150</span>
                     <span tagx="fpage">1405</span>
                     <span tagx="lpage">1407</span>
                     <span class="pub-id'">[8102511]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B12"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Lohr</span>
                           <span tagx="given-names">JB</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Caligiuri</span>
                           <span tagx="given-names">MP</span>,
                        </span>
                     </span>
                     <span tagx="article-title">A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia</span>
                     <span tagx="source">J Clin Psychiatry</span>
                     <span tagx="year">1996</span>
                     <span tagx="volume">57</span>
                     <span tagx="fpage">167</span>
                     <span tagx="lpage">173</span>
                     <span class="pub-id'">[8601552]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B13"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Shriqui</span>
                           <span tagx="given-names">CL</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Bradwejn</span>
                           <span tagx="given-names">J</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Annable</span>
                           <span tagx="given-names">L</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled
                        study
                     </span>
                     <span tagx="source">Am J Psychiatry</span>
                     <span tagx="year">1992</span>
                     <span tagx="volume">149</span>
                     <span tagx="fpage">391</span>
                     <span tagx="lpage">393</span>
                     <span class="pub-id'">[1346951]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B14"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Bandelow</span>
                           <span tagx="given-names">B</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Meier</span>
                           <span tagx="given-names">A</span>,
                        </span>
                     </span>
                     <span tagx="article-title">Aripiprazole, a "Dopamine-Serotonin System Stabilizer" in the treatment of Psychosis</span>
                     <span tagx="source">Reprinted from the German Journal of Psychiatry</span>
                     <div tagxxx="ext-link"></div>
                     <div tagxxx="comment">ISSN 1433-1055</div>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B15"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Demopoulos</span>
                           <span tagx="given-names">VJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Gavalas</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Rekatas</span>
                           <span tagx="given-names">G</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Tani</span>
                           <span tagx="given-names">Ek</span>,
                        </span>
                     </span>
                     <span tagx="article-title">Activity on the cns andantioxidant profile of two benzo[g]indolamine derivatives</span>
                     <span tagx="source">Med Chem Res</span>
                     <span tagx="year">1999</span>
                     <span tagx="volume">9</span>
                     <span tagx="fpage">9</span>
                     <span tagx="lpage">18</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B16"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Albert</span>
                           <span tagx="given-names">A</span>,
                        </span>
                     </span>
                     <span tagx="source">Selective Toxicity, The physico-chemical basis of therapy</span>
                     <span tagx="year">1985</span>
                     <div tagxxx="edition">7</div>
                     <span class="publisher-name'">[New York: Chapman and Hall]</span>
                     <span tagx="fpage">294</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B17"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Gerlach</span>
                           <span tagx="given-names">M</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Riederer</span>
                           <span tagx="given-names">P</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Youdim</span>
                           <span tagx="given-names">MBH</span>,
                        </span>
                     </span>
                     <span tagx="article-title">Neuroprotective Therapeutic Strategies-Comparison of experimental and Clinical Results</span>
                     <span tagx="source">Biochem Pharmacol</span>
                     <span tagx="year">1995</span>
                     <span tagx="volume">50</span>
                     <span tagx="fpage">1</span>
                     <span tagx="lpage">16</span>
                     <span class="pub-id'">[7605334]</span>
                     <span class="pub-id'">[10.1016/0006-2952(95)00051-Z]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B18"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Demopoulos</span>
                           <span tagx="given-names">VJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Gavalas</span>
                           <span tagx="given-names">A</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Rekatas</span>
                           <span tagx="given-names">G</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Tani</span>
                           <span tagx="given-names">Ek</span>,
                        </span>
                     </span>
                     <span tagx="article-title">Synthesis of 6,7,8,9-Tetrahydro-N,N-Fi-Propyl-1H-Benz[g]indol-7-amine. A Potential
                        Dopamine Receptor Agonist
                     </span>
                     <span tagx="source">J Heterocyclic Chem</span>
                     <span tagx="year">1995</span>
                     <span tagx="volume">32</span>
                     <span tagx="fpage">1145</span>
                     <span tagx="lpage">1148</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B19"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Rekka</span>
                           <span tagx="given-names">E</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Kolstee</span>
                           <span tagx="given-names">J</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Timmerman</span>
                           <span tagx="given-names">H</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Bast</span>
                           <span tagx="given-names">A</span>,
                        </span>
                     </span>
                     <span tagx="article-title">The effect of some H-2-receptor Antagonists on rat Hepatic Microsomal cytochrome P-450
                        and lipid Peroxidation in vitro
                     </span>
                     <span tagx="source">Eur J Med Chem</span>
                     <span tagx="year">1989</span>
                     <span tagx="volume">24</span>
                     <span tagx="fpage">43</span>
                     <span tagx="lpage">47</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B20"></a>
                  <div tagxxx="citation">
                     <span tagx="article-title">ClogP Version 4.72</span>
                     <span tagx="source">Daylight Chemical Information Systems Inc</span>
                     <div tagxxx="ext-link"></div>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B21"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Demopoulos</span>
                           <span tagx="given-names">VJ</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Anagnostou</span>
                           <span tagx="given-names">C</span>,
                        </span>
                        <span class="name'">
                           <span tagx="surname">Nicolaou</span>
                           <span tagx="given-names">I</span>,
                        </span>
                     </span>
                     <span tagx="article-title">Validation of a computational procedure for the calculation of the polar surface area
                        (PSA) of organic compounds
                     </span>
                     <span tagx="source">Pharmazie</span>
                     <span tagx="year">2002</span>
                     <span tagx="volume">57</span>
                     <span tagx="fpage">652</span>
                     <span tagx="lpage">653</span>
                     <span class="pub-id'">[12369459]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B22"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Clark</span>
                           <span tagx="given-names">DE</span>,
                        </span>
                     </span>
                     <span tagx="article-title">Rapid calculation of polar molecular surface area and its application to the prediction
                        of transport phenomena. 2. Prediction of blood-brain barrier penetration
                     </span>
                     <span tagx="source">J Pharm Sci</span>
                     <span tagx="year">1999</span>
                     <span tagx="volume">88</span>
                     <span tagx="fpage">815</span>
                     <span tagx="lpage">821</span>
                     <span class="pub-id'">[10430548]</span>
                     <span class="pub-id'">[10.1021/js980402t]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B23"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Clark</span>
                           <span tagx="given-names">DE</span>,
                        </span>
                     </span>
                     <span tagx="article-title">Rapid calculation of polar molecular surface area and its application to the prediction
                        of transport phenomena. 1. Prediction of intestinal absorption
                     </span>
                     <span tagx="source">J Pharm Sci</span>
                     <span tagx="year">1999</span>
                     <span tagx="volume">88</span>
                     <span tagx="fpage">808</span>
                     <span tagx="lpage">814</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B24"></a>
                  <div tagxxx="citation">
                     <span tagx="article-title">SPARTAN SGI Version 5.1.3 OpenGL, Wavefunction, Inc., 18401 Von Karman Avenue, Suite
                        370, Irvine, CA 92612 U.S.A
                     </span>
                     <div tagxxx="comment">[Method: RHF/6-311G** on a low energy conformer generated from a Monte Carlo search]</div>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B25"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Jackson-Lewis</span>
                           <span tagx="given-names">V</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Partial Attenuation of Chronic Fluphenazine-induced Changes in Regional Monoamine
                        Metabolism by D-Alpha-Tocopherol in Rat-brain
                     </span>
                     <span tagx="source">Brain Res Bull</span>
                     <span tagx="year">1991</span>
                     <span tagx="volume">26</span>
                     <span tagx="fpage">251</span>
                     <span tagx="lpage">258</span>
                     <span class="pub-id'">[1707329]</span>
                     <span class="pub-id'">[10.1016/0361-9230(91)90235-C]</span>
                  </div>
               </li>
               <li tag="ref">
                  <a name="B26"></a>
                  <div tagxxx="citation">
                     <span class="person-group'">
                        <span class="name'">
                           <span tagx="surname">Vatassery</span>
                           <span tagx="given-names">GT</span>,
                        </span>
                        <i>et al.</i>
                     </span>
                     <span tagx="article-title">Concentrations of Vitamin E in various Neuroanatomical Regions and Subcellular Fractions,
                        and The Uptake of Vitamin E by specific Areas of Rat Brain
                     </span>
                     <span tagx="source">Biochim Biophys Acta</span>
                     <span tagx="year">1984</span>
                     <span tagx="volume">792</span>
                     <span tagx="fpage">118</span>
                     <span tagx="lpage">122</span>
                     <span class="pub-id'">[6696923]</span>
                     <span class="pub-id'">[10.1016/0005-2760(84)90211-X]</span>
                  </div>
               </li>
            </ul>
         </div>
      </div>
   </div>
</html>